JOURNAL OF DRUGS AND PHARMACEUTICAL SCIENCE
Integrity Research Journals
ISSN: 2705-2222
Model: Open Access/Peer Reviewed
DOI: 10.31248/JDPS
Start Year: 2016
Email: jdps@integrityresjournals.org
Affordability issues of biotech drugs in low- and middle-income countries
https://doi.org/10.31248/JDPS2019.025 | Article Number: 2682498D1 | Vol.3 (3) - August 2019
Received Date: 22 July 2019 | Accepted Date: 26 July 2019 | Published Date: 30 August 2019
Author: Abdul Kader Mohiuddin
Pharmaceutical companies invest in the development and testing of their drugs including funding clinical trials. Furthermore, pharmaceutical companies also spend a large amount of money on advertising. For instance, in 2016 US$6.7 billion was spent on direct-to-consumer pharmaceutical advertising alone in the USA. Worldwide spending on medicines reached $1.2 trillion in 2018 and will exceed $1.5 trillion by 2023, according to “The Global Use of Medicine in 2019 and Outlook to 2023”. Although, access to essential medicines is problematic for one third of all persons worldwide. Limited access to essential medicines (EMs) for treating chronic diseases is a major challenge in low- and middle-income countries (LMICs)
| Ahmadiani, S., & Nikfar, S. (2016). Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. DARU Journal of Pharmaceutical Sciences, 24(1), 13. Crossref |
||||
| Aitken, M., Kleinrock, M., Simorellis, A., & Nass, D. (2019). The global use of medicine in 2019 and outlook to 2023. Forecasts and Areas to Watch. Institute Report, January 29, 2019. | ||||
| Ba-Nguz, A., Shah, A., Bresee, J. S., Lafond, K. E., Cavallaro, K., Shefer, A., Donadel, M., & Seward, J. F. (2019). Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health's Partnership for influenza vaccine introduction. Vaccine, 37(28), 3646-3653. Crossref |
||||
| Barrios, C. H., Reinert, T., & Werutsky, G. (2019). Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecancermedicalscience, 13, 898. Crossref |
||||
| Beck, E. J., Mandalia, S., DongmoNguimfack, B., Pinheiro, E., 't Hoen, E., Boulet, P., Stover, J., Gupta, A., Juneja, S., Habiyambere, V., & Ghys, P. (2019). Does the political will exist to bring quality-assured and affordable drugs to low-and middle-income countries? Global Health Action, 12(1), 1586317. Crossref |
||||
| Chivukula, M. V., & Tisocki, K. (2018). Essential cancer medicines in the national lists of countries of the WHO South- East Asia Region: a descriptive assessment. WHO South-East Asia Journal of Public Health, 7(2), 90-98. Crossref |
||||
| Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products (CUGPHISFCP) (2013). Weaknesses in the drug distribution chain. In: Countering the problem of falsified and substandard drugs. Buckley G. J., & Gostin L. O. (eds.). Board on Global Health; Institute of Medicine, Washington (DC): National Academies Press (US). Link |
||||
| Dhillon, P. K., Mathur, P., Nandakumar, A., Fitzmaurice, C., Kumar, G. A., Mehrotra, R., Shukla, D.K., Rath, G. K., Gupta, P. C., Swaminathan, R., & Thakur, J. S. (2018). The burden of cancers and their variations across the states of India: The Global Burden of Disease Study 1990-2016. The Lancet Oncology, 19(10), 1289-1306. Crossref |
||||
| Edelman, B. (2004). Explaining the cost of biotech therapies. Biotechnology Healthcare, 1(2), 37. | ||||
| Eniu, A., Torode, J., Magrini, N., & Bricalli, G. (2016). Back to the 'essence'of medical treatment in oncology: The 2015 WHO Model List of Essential Medicines, ESMO Open, 1, e000030. Crossref |
||||
| Ezziane, Z. (2014). Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges. International Journal of Health Policy and Management, 3(7), 365-370. Crossref |
||||
| Faruqui, N., Martiniuk, A., Sharma, A., Sharma, C., Rathore, B., Arora, R. S., & Joshi, R. (2019). Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. BMJ Global Health, 4(2), e001379. Crossref |
||||
| Giri, M., Giri, M., Thapa, R. J., Upreti, B., & Pariyar, B. (2018). Breast Cancer in Nepal: Current status and future directions. Biomedical Reports, 8(4), 325-329. Crossref |
||||
| Goldman, D. P., Joyce, G. F., Lawless, G., Crown, W. H., & Willey, V. (2006). Benefit design and specialty drug use. Health Affairs, 25(5), 1319-1331. Crossref |
||||
| Goldstein, D. A., Clark, J., Tu, Y., Zhang, J., Fang, F., Goldstein, R., Stemmer, S. M., & Rosenbaum, E. (2017). A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget, 8(42), 71548. Crossref |
||||
| Gouglas, D., Le, T. T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J. M., Heaton, P. M., & Røttingen, J. A. (2018). Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. The Lancet Global Health, 6(12), e1386-e1396. Crossref |
||||
| Gyawali, B. (2017). Cancer drugs in LMICs: Cheap but unaffordable. Oncotarget, 8(52), 89425-89426. Crossref |
||||
| Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. S., & Grootendorst, P. (2019). Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases, 14(1), 12. Crossref |
||||
| Kaduskar, P. U. (2016). Biosimilar insulins: an unavoidable option in South-East Asia. Indian Journal of Endocrinology and Metabolism, 20(4), 574-575. Crossref |
||||
| Kalra, S., Khan, A. A., Raza, S. A., Somasundaram, N., Shrestha, D., Latif, Z. A., Bajaj, S., Pathan, M.F., Sahay, R., & Mahtab, H. (2016). Biosimilar insulins: informed choice for South Asia. Indian Journal of Endocrinology and Metabolism, 20(1), 5-8. Crossref |
||||
| Kaufman, H. L., Atkins, M. B., Subedi, P., Wu, J., Chambers, J., Mattingly, T. J., Campbell, J.D., Allen, J., Ferris, A. E., Schilsky, R. L., & Danielson, D. (2019). The promise of Immuno-oncology: Implications for defining the value of cancer treatment. Journal for Immunotherapy of Cancer, 7(1), 129. Crossref |
||||
| Khuluza, F., & Haefele-Abah, C. (2019). The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study. PloS one, 14(2), e0212125. Crossref |
||||
| Kolasani, B. P., Malathi, D. C., & Ponnaluri, R. R. (2016). Variation of cost among anti-cancer drugs available in Indian market. Journal of Clinical and Diagnostic Research, 10(11), FC17-FC20. Crossref |
||||
| Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., O'Neill, K. M., Balter, M. L., Fritz, Z. R., Androulakis, I. P., Schloss, R. S., & Yarmush, M. L. (2018). The growing role of precision and personalized medicine for cancer treatment. Technology, 6(3 & 4), 79-100. Crossref |
||||
| Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019). Cancer drug development: The missing links. Experimental Biology and Medicine, 244(8), 663-689. Crossref |
||||
| Lexchin, J. (2013). Canada and access to medicines in developing countries: intellectual property rights first. Globalization and health, 9(1), 42. Crossref |
||||
| Mohiuddin, A. K. (2019). Safety issues of biosimilar products. Pharmacology, Toxicology and Pharmaceutics Open Access Open Journal, 1(1), 6-8. Crossref |
||||
| Moon, S. (2017). Powerful ideas for global access to medicines. New England Journal of Medicine, 376(6), 505-507. Crossref |
||||
| Moreno, S. G., & Epstein, D. (2019). The price of innovation-the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. Journal of Market Access & Health Policy, 7(1), 1583536. Crossref |
||||
| Oberoi, S. S., & Oberoi, A. (2014). Pharmacoeconomics guidelines: The need of hour for India. International Journal of Pharmaceutical Investigation, 4(3), 109-111. Crossref |
||||
| Owoeye, O., & Owoeye, O. (2018). Biologics and Public Health: Prospects and Challenges. Journal of law and medicine, 26(1), 170-187. | ||||
| Paudel, S., Owen, A. J., Owusu-Addo, E., & Smith, B. J. (2019). Physical activity participation and the risk of chronic diseases among South Asian adults: A systematic review and meta-analysis. Scientific Reports, 9(1), 9771. Crossref |
||||
| Philippidis, A. (2019). Top 15 Best-Selling Drugs of 2018: Sales for most treatments grow year-over-year despite concerns over rising prices. Genetic Engineering & Biotechnology News, 39(4), 16-17. Crossref |
||||
| Prinja, S., Bahuguna, P., Tripathy, J. P., & Kumar, R. (2015). Availability of medicines in public sector health facilities of two North Indian States. BMC Pharmacology and Toxicology, 16(1), 43. Crossref |
||||
| Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013). Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Affairs, 32(6), 1143-1152. Crossref |
||||
| Rijal, A., Adhikari, T. B., Khan, J. A., & Berg-Beckhoff, G. (2018). The economic impact of non-communicable diseases among households in South Asia and their coping strategy: A systematic review. PloS one, 13(11), e0205745. Crossref |
||||
| Salmasi, S., Lee, K. S., Ming, L. C., Neoh, C. F., Elrggal, M. E., Khan, T. M., & Hadi, M. A. (2017). Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean region. BMC cancer, 17(1), 903. Crossref |
||||
| Sankaranarayanan, R., Bhatla, N., Gravitt, P. E., Basu, P., Esmy, P. O., Ashrafunnessa, K. S., Ariyaratne, Y., Shah, A., & Nene, B. M. (2008). Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine, 26, M43-M52. Crossref |
||||
| Saqib, A., Iftikhar, S., & Sarwar, M. R. (2018). Availability and affordability of biologic versus non-biologic anticancer medicines: A cross-sectional study in Punjab, Pakistan. BMJ Open, 8(6), e019015. Crossref |
||||
| Scavone, C., di Mauro, G., Mascolo, A., Berrino, L., Rossi, F., & Capuano, A. (2019). The new paradigms in clinical research: from Early Access Programs to the novel therapeutic approaches for unmet medical needs. Frontiers in Pharmacology, 10, 111. Crossref |
||||
| Scavone, C., Sportiello, L., Sullo, M. G., Ferrajolo, C., Ruggiero, R., Sessa, M., Berrino, P.M., di Mauro, G., Berrino, L., Rossi, F., & Rafaniello, C. (2017). Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania region (Italy): bio-cam observational study. Frontiers in pharmacology, 8, 607. Crossref |
||||
| Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a cancer journal for clinicians, 69(1), 7-34. Crossref |
||||
| Simon, R. (2017). Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clinical Pharmacology & Therapeutics, 102(6), 934-941. Crossref |
||||
| Stevens, H., & Huys, I. (2017). Innovative approaches to increase access to medicines in developing countries. Frontiers in Medicine, 4, 218. Crossref |
||||
| Tay-Teo, K., Ilbawi, A., & Hill, S. R. (2019). Comparison of sales income and research and development costs for fda-approved cancer drugs sold by originator drug companies. JAMA Network Open, 2(1), e186875-e186875. Crossref |
||||
| Thomas, Z., Saha, G. K., Gopakumar, K. M., & Ganguly, N. K. (2019). Can India lead the way in neglected diseases innovation? BMJ, 364, k5396. Crossref |
||||
| 't Hoen, E. F. M., Kujinga, T., & Boulet, P. (2018). Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region. Journal of Pharmaceutical Policy and Practice, 11(1), 31. Crossref |
||||
| van der Gronde, T., Uyl-de Groot, C. A., & Pieters, T. (2017). Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PloS one, 12(8), e0182613. Crossref |
||||
| Vogenberg, F. R., & Young, C. (2004). Biotech injectable drugs: Clinical applications and financial effects. Biotechnology Healthcare, 1(3), 31-40. | ||||
| Wilking, N., Lopes, G., Meier, K., Simoens, S., van Harten, W., & Vulto, A. (2017). Can we continue to afford access to cancer treatment? European Oncology and Haematology, 13(2),114-119. Crossref |
||||
Copyright © 2025 Integrity Research Journals. All rights reserved.